Sentiment Trading

Amgen Inc. experienced significant developments in the week of October 23, 2025, including a shareholder rights inquiry, regulatory approval for its respiratory therapy Tezspire, and recognition in the thrombocytopenia market, with its share price r…

Amgen Inc. has exceeded expectations with a 9% revenue increase, prompting a revised 2025 revenue forecast and a $500 million share repurchase program.

Amgen Inc. reports a 9% increase in total revenues to $9.2 billion in Q2 2025, driven by its commitment to delivering innovative medicines and biosimilars.

Amgen Inc. has announced promising results from its Phase 2 obesity study of MariTide, a potential groundbreaking treatment for obesity, particularly in patients with type 2 diabetes.